Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Rasagiline
Drug ID BADD_D02441
Description Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
Indications and Usage For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.
Marketing Status approved
ATC Code N04BD02
DrugBank ID DB01367
KEGG ID D08469; D10829
MeSH ID C031967
PubChem ID 3052776
TTD Drug ID D06OMW
NDC Product Code 16714-770; 0093-3061; 67877-260; 47781-683; 42291-780; 67877-259; 16714-771; 0093-3060; 42571-221; 47781-690; 42571-220; 42291-779
UNII 003N66TS6T
Synonyms rasagiline | N-2-propynyl-1-indanamine | AGN 1135 | AGN-1135 | TVP 1022 | TVP1022 | TVP-1022 | N-propargyl-1-aminoindan mesylate | rasagiline hydrochloride | TVP 101 | TVP-101 | 2,3-dihydro-N-2-propynyl-1H-inden-1-amine-(1R)-hydrochloride | Azilect
Chemical Information
Molecular Formula C12H13N
CAS Registry Number 136236-51-6
SMILES C#CCNC1CCC2=CC=CC=C12
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Presyncope02.11.04.013; 24.06.02.010; 17.02.05.0090.003572%
Psychomotor hyperactivity19.11.02.003; 17.01.02.0110.004384%Not Available
Raynaud's phenomenon24.04.03.0030.001624%Not Available
Respiratory depression22.02.01.010; 17.02.05.0470.001624%Not Available
Restlessness19.11.02.002; 17.02.05.0210.001624%
Rhabdomyolysis15.05.05.0020.002436%
Seizure17.12.03.0010.005683%
Serotonin syndrome17.05.02.004; 15.05.04.016; 12.03.01.0410.014938%Not Available
Sleep attacks19.02.02.0050.002436%Not Available
Sleep disorder19.02.04.0010.003572%Not Available
Somnolence19.02.05.003; 17.02.04.0060.021596%
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.0030.005196%Not Available
Subarachnoid haemorrhage17.08.01.010; 12.01.10.011; 24.07.04.0040.004871%Not Available
Sudden death08.04.01.003; 02.03.04.0130.001624%
Syncope02.11.04.015; 24.06.02.012; 17.02.04.0080.012178%
Tachycardia02.03.02.0070.002436%Not Available
Transient ischaemic attack17.08.04.001; 24.04.06.0050.001624%
Tremor17.01.06.0020.013152%
Vertigo17.02.12.002; 04.04.01.0030.001624%
Withdrawal syndrome08.06.02.012; 19.07.06.0230.004384%Not Available
Mobility decreased15.03.05.023; 17.02.05.018; 08.01.03.0300.003247%Not Available
Musculoskeletal disorder15.03.05.0250.001624%Not Available
General physical health deterioration08.01.03.0180.006495%Not Available
Shock haemorrhagic14.05.05.003; 24.06.02.0140.004059%Not Available
Balance disorder08.01.03.081; 17.02.02.0070.005683%Not Available
Sudden onset of sleep17.15.04.0030.009742%Not Available
Dysstasia17.02.02.012; 15.03.05.011; 08.01.03.0890.002436%Not Available
Lower gastrointestinal haemorrhage07.12.03.011; 24.07.02.0300.001624%
Musculoskeletal stiffness15.03.05.0270.005196%Not Available
Depressive symptom19.15.02.0030.001624%Not Available
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages